Novartis investigative site

Albany, New York 12208

0 studies enrolling now · 18 studies all time

What they study most

Acute Lymphoblastic Leukemia (ALL), Alzheimer Disease, Arthritis, Psoriatic, Cancer, Cardiovascular Disease, Cardiovascular Disease and Lipoprotein(a), Chronic Myelogenous Leukemia (CML), Chronic Obstructive Pulmonary Disease, Cystic Fibrosis, Diabetic Nephropathy, Metastatic Gastrointestinal Stromal Tumors (GIST), Multiple Sclerosis

Studies at this site

• Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study — Completed
• Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy — Completed
• Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis — Completed
• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies — Completed
• Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo — Completed
• Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis — Completed
• Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. — Completed
• A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) — Completed
• A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation — NO_LONGER_AVAILABLE
• 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis — Completed
• MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone — Stopped early
• 24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis — Completed
• 16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients — Completed
• Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases) — Stopped early
• Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline — Completed
• Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis — Completed
• A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD) — Completed